Gyre Therapeutics, Inc. (GYRE) P/E Ratio History
Historical price-to-earnings valuation from 2007 to 2025
Loading P/E history...
GYRE Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Gyre Therapeutics, Inc. (GYRE) trades at a price-to-earnings ratio of 314.2x, with a stock price of $7.07 and trailing twelve-month earnings per share of $0.01.
The current P/E is 18% below its 5-year average of 384.9x. Over the past five years, GYRE's P/E has ranged from a low of 46.8x to a high of 1078.8x, placing the current valuation at the 64th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, GYRE trades at a 1308% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, GYRE commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GYRE DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
GYRE P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 25.5 | 1.11 | -25% | |
| $4B | 9.9 | - | +68% | |
| $2B | 6.9Lowest | 0.67Best | +817% | |
| $7B | 15.5 | - | +1747%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
GYRE Historical P/E Data (2007–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $7.06 | $0.02 | 313.8x | -18% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $7.20 | $0.15 | 46.8x | -88% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $5.25 | $0.05 | 111.5x | -71% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $3.15 | $0.04 | 73.3x | -81% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $7.95 | $0.05 | 171.3x | -55% |
| FY2011 Q2 | $33185.25 | $36.23 | 916.0x | +138% | |
| FY2011 Q1 | $41879.25 | $57.59 | 727.2x | +89% | |
| FY2010 Q4 | Fri Dec 31 2010 00:00:00 GM | $41737.50 | $38.69 | 1078.8x | +180% |
| FY2007 Q3 | Sun Sep 30 2007 00:00:00 GM | $14159.25 | $42.13 | 336.1x | -13% |
| FY2007 Q2 | Sat Jun 30 2007 00:00:00 GM | $14411.25 | $53.92 | 267.3x | -31% |
| FY2007 Q1 | Sat Mar 31 2007 00:00:00 GM | $13104.00 | $68.15 | 192.3x | -50% |
Average P/E for displayed period: 384.9x
See GYRE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GYRE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GYRE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGYRE — Frequently Asked Questions
Quick answers to the most common questions about buying GYRE stock.
Is GYRE stock overvalued or undervalued?
GYRE trades at 314.2x P/E, near its 5-year average of 384.9x. The 64th percentile ranking places valuation within normal historical bounds.
How does GYRE's valuation compare to peers?
Gyre Therapeutics, Inc. P/E of 314.2x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is GYRE's PEG ratio?
GYRE PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2007-2025.